05:58 AM EDT, 04/30/2024 (MT Newswires) -- Amgen ( AMGN ) and Sandoz reached an agreement to resolve their patent disputes related to Sandoz's denosumab biosimilars, according to a Tuesday statement from Sandoz.

In May 2023 patent infringement proceedings, Amgen ( AMGN ) claimed that Sandoz infringed up to 21 patents covering its reference medicines Prolia and Xgeva.

Sandoz said the settlement deal will allow it to enter the US market with a biosimilar version of Prolia and Xgeva on May 31, 2025, or earlier under certain circumstances.

No other settlement terms were disclosed.

Price: 276.26, Change: -0.12, Percent Change: -0.04